BioVie 3Q 2026: EPS ($0.68) — 10-Q Summary
BioVie reported a wider quarterly loss of $5.61M, or $0.68 per share, due to increased R&D expenses and lower interest income. The company is pre-revenue. Key programs, including Parkinson's disease and Long COVID, showed positive results. The Phase 3 liver program protocol is being finalized. According to the company, R&D expenses rose primarily due to the Long COVID Phase 2 program.
How this was made

The 30-second read
Why it matters
The wider loss and R&D spend increase signal short‑term cash burn, but the trial readouts provide data points for future valuation.
Market read
The filing provides fresh earnings data and trial updates that can move the stock, making it a relevant short‑term trading catalyst.
What to watch
Potential future partnership or licensing deals for the Long COVID program could mitigate the current loss.
Background
BioVie is a pre‑revenue biotech focused on neuro‑degenerative and post‑viral conditions, trading on Nasdaq under BIVI.
Ticker impact
BioVie reported a wider quarterly loss and new Phase 2 trial results for its Long COVID and Parkinson's programs in its 10‑Q filing.
likely downward pressure as the market prices in the larger loss and modest trial outcomes
Earnings miss and widened loss are fresh material; investors typically react negatively to higher expenses and lack of revenue.
Market effects
Highlights ongoing challenges for biotech firms developing Long COVID therapies, may temper enthusiasm for similar small‑cap pipelines.
Limited to US biotech sector; no broader regional effect.
Minimal global impact; primarily relevant to investors in US biotech microcaps.
Counterpoint
If the Phase 2 data shows statistically significant improvements in high‑symptom subgroups, the long‑term upside could outweigh the near‑term loss.
Key entities
- companyBioVie Inc.
Biotech firm reporting its Q3 2026 10‑Q results.


